Loading...

Large Pharma Partnerships And AI Platforms Will Open New Markets

Published
30 Apr 25
Updated
28 Aug 25
AnalystConsensusTarget's Fair Value
€9.58
37.4% undervalued intrinsic discount
28 Aug
€6.00
Loading
1Y
-10.1%
7D
-1.9%

Author's Valuation

€9.6

37.4% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on21 Aug 25
Fair value Decreased 13%

The notable reduction in Evotec’s Analyst Price Target reflects a lower expected future P/E and a slight moderation in revenue growth forecasts, leading to a new consensus fair value of €9.43. What's in the News Evotec lowered FY2025 revenue guidance to EUR 760–800 million (previously EUR 840–880 million) due to changes in revenue mix and higher-than-expected cost savings; technology licensing is expected to contribute more, while Shared R&D faces market challenges.